Roivant SciencesROIV
ROIV
About: Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
Employees: 908
0
Funds holding %
of 7,425 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
65% more first-time investments, than exits
New positions opened: 66 | Existing positions closed: 40
8% more funds holding
Funds holding: 290 [Q3] → 313 (+23) [Q4]
2% more capital invested
Capital invested by funds: $6.52B [Q3] → $6.65B (+$136M) [Q4]
0.9% more ownership
Funds ownership: 76.37% [Q3] → 77.26% (+0.9%) [Q4]
0% more funds holding in top 10
Funds holding in top 10: 17 [Q3] → 17 (+0) [Q4]
9% less repeat investments, than reductions
Existing positions increased: 93 | Existing positions reduced: 102
14% less call options, than puts
Call options by funds: $9.58M | Put options by funds: $11.1M
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$18
55%
upside
Avg. target
$18
55%
upside
High target
$18
55%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Douglas Tsao 26% 1-year accuracy 44 / 171 met price target | 55%upside $18 | Buy Reiterated | 21 Apr 2025 |
Financial journalist opinion
Based on 4 articles about ROIV published over the past 30 days
Positive
Seeking Alpha
1 week ago
Roivant Sciences: Primed For Growth With A De-Risked Pipeline
Roivant Sciences has strengthened its financial position through strategic divestitures, boasting $5.2 billion in cash and assets, enabling robust funding for its late-stage pipeline. The company's FcRn inhibitor platform, led by IMVT-1402, shows promise in autoimmune diseases, with positive clinical readouts validating its potential. Priovant's brepocitinib, targeting TYK2/JAK1 pathways, is advancing in Phase 3 trials for Dermatomyositis and Non-Infectious Uveitis, addressing significant unmet needs.
Negative
Investors Business Daily
1 week ago
Immunovant Crumbles After Roivant Sweeps Out Its C-Suite, Unveils Strategic Shift
Roivant Sciences is making serious changes to subsidiary Immunovant, announcing Monday a series of C-suite changes and new disease targets.
Neutral
GlobeNewsWire
1 week ago
Immunovant Announces Next Phase of Growth with Roivant Including Changes to its Leadership Team and Additional Indications Sjögren's Disease (SjD) and Cutaneous Lupus Erythematosus (CLE) for IMVT-1402
NEW YORK, April 21, 2025 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced next phase of growth including changes to its leadership team and the expanded development of IMVT-1402 into two new indications, SjD and CLE.
Neutral
GlobeNewsWire
1 week ago
Immunovant Announces Next Phase of Growth with Roivant Including Changes to its Leadership Team and Additional Indications Sjögren's Disease (SjD) and Cutaneous Lupus Erythematosus (CLE) for IMVT-1402
Eric Venker, M.D. (currently President and COO of Roivant) appointed as CEO of Immunovant and Tiago Girao appointed as CFO of Immunovant Pete Salzmann, M.D.
Positive
Investors Business Daily
1 month ago
Roivant, Immunovant Succeed In Phase 3. But There's A Twist — And Shares Tumbled.
Immunovant and Roivant Sciences said Wednesday their rare disease drug succeeded in a final-phase study, but the duo won't seek approval. The post Roivant, Immunovant Succeed In Phase 3.
Neutral
GlobeNewsWire
1 month ago
Roivant Announces Positive Results for Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Studies
NEW YORK, March 19, 2025 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today reported topline results from its Phase 3 study of batoclimab in MG and initial results from Period 1 of its Phase 2b study in CIDP.
Neutral
GlobeNewsWire
1 month ago
Roivant to Host Investor Webcast at 8:00 AM ET on Wednesday, March 19 to Review Results from Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Programs
NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced that it will host an investor webcast on Wednesday, March 19th at 8:00 a.m. ET to review results from its Phase 3 study of batoclimab in MG and initial results from its Phase 2b study in CIDP.
Positive
Zacks Investment Research
1 month ago
Wall Street Analysts Believe Montes Archimedes Acquisition (ROIV) Could Rally 60%: Here's is How to Trade
The consensus price target hints at a 60% upside potential for Montes Archimedes Acquisition (ROIV). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Neutral
GlobeNewsWire
1 month ago
Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against Moderna
BASEL, Switzerland and VANCOUVER, B.C. and WARMINSTER, Pa., March 03, 2025 (GLOBE NEWSWIRE) -- Genevant Sciences, a leading nucleic acid delivery company with world-class platforms and a robust lipid nanoparticle (LNP) patent portfolio (a subsidiary of Roivant Sciences, Ltd. (Nasdaq: ROIV)), and Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company focused on infectious disease, today filed five international lawsuits seeking to enforce patents protecting their innovative LNP technology against Moderna, Inc. and certain affiliates. Together, the enforcement actions target alleged infringing activities in 30 countries.
Positive
Zacks Investment Research
2 months ago
All You Need to Know About Montes Archimedes Acquisition (ROIV) Rating Upgrade to Buy
Montes Archimedes Acquisition (ROIV) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Charts implemented using Lightweight Charts™